Gamida Cell (NASDAQ:GMDA – Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Risk and Volatility
Gamida Cell has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.
This is a summary of current ratings and price targets for Gamida Cell and X4 Pharmaceuticals, as provided by MarketBeat.
|Strong Buy Ratings
Valuation and Earnings
This table compares Gamida Cell and X4 Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Earnings Per Share
Gamida Cell has higher revenue and earnings than X4 Pharmaceuticals. Gamida Cell is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
42.7% of Gamida Cell shares are owned by institutional investors. Comparatively, 78.5% of X4 Pharmaceuticals shares are owned by institutional investors. 6.7% of Gamida Cell shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Gamida Cell and X4 Pharmaceuticals’ net margins, return on equity and return on assets.
|Return on Equity
|Return on Assets
Gamida Cell beats X4 Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
About Gamida Cell
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.